文献速递心血管胸部PETMR

结节病中肺动脉18F-氟脱氧葡萄糖PET/CMR摄取作为肺动脉高压标志物的研究

Pulmonary Artery 18F-Fluorodeoxyglucose Uptake by PET/CMR as a Marker of Pulmonary Hypertension in Sarcoidosis.
PubMed 文献 · JACC Cardiovasc Imaging · 2021-07-14

单中心175例疑似心脏结节病患者行胸部PET/CMR,33例肺动脉壁可见18F-FDG摄取;摄取组右心导管平均肺动脉压高于无摄取组(34.4 vs 25.6 mm Hg,P=0.003),且肺动脉高压比例更高;定性评估摄取区分肺动脉高压的敏感度33%、特异度96%,摄取强度与肺动脉压相关。

要点

  • 肺动脉壁18F-FDG摄取定性评估区分右心导管诊断的肺动脉高压,敏感度33%、特异度96%。
  • 有肺动脉摄取者右心导管平均肺动脉压34.4±7.2 mm Hg,无摄取者25.6±9.3 mm Hg(P=0.003)。
  • 肺动脉壁SUVmax与TBR和右心导管和/或经胸超声心动图估测的肺动脉压相关。

核心结论

  • PET/CMR显示的肺动脉18F-FDG摄取与肺动脉高压相关,且其强度与肺动脉压相关。

研究设计与样本

  • 单中心队列,175例疑似心脏结节病患者行胸部混合PET/CMR,按SUVmax和靶本比定量肺动脉18F-FDG摄取,并与右心导管或经胸超声心动图结果比较。

关键影像表现/征象

  • 33例受试者肺动脉壁可见明确的18F-FDG摄取。
  • 右心导管亚组(n=10)中,有肺动脉摄取组平均肺动脉压34.4±7.2 mm Hg,无摄取组25.6±9.3 mm Hg(P=0.003)。
  • 经胸超声心动图亚组中,有肺动脉摄取组出现肺动脉高压征象14例(51.9%),无摄取组37例(29.8%)(P<0.05)。

诊断标准与关键数值

  • 以右心导管平均肺动脉压25 mm Hg为阈值,有肺动脉18F-FDG摄取者9例(90%)存在肺动脉高压,无摄取组18例(45%)(P<0.05)。
  • 肺动脉壁18F-FDG摄取定性评估区分右心导管肺动脉压定义的肺动脉高压,敏感度33%、特异度96%。

临床应用与阅片要点

  • 在疑似心脏结节病的PET/CMR阅片时,注意观察肺动脉壁有无18F-FDG摄取,并可用SUVmax和靶本比定量。
  • 肺动脉壁摄取定性评估特异度高(96%)但敏感度低(33%),阳性提示肺动脉高压可能性大,阴性不能排除。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVES: This study investigated whether pulmonary artery (PA) 18F-FDG uptake is associated with hypertension, and if it correlates to elevated pulmonary pressures.

BACKGROUND: 18F-fluorodeoxyglucose (FDG) positron emission tomography (PET) combined with computed tomography or cardiac magnetic resonance (CMR) has been used to assess inflammation mostly in large arteries of the systemic circulation. Much less is known about inflammation of the vasculature of the pulmonary system and its relationship to pulmonary hypertension (PH).

METHODS: In a single-center cohort of 175 patients with suspected cardiac sarcoidosis, who underwent hybrid thoracic PET/CMR, 18F-FDG uptake in the PA was quantified according to maximum standardized uptake value (SUVmax) and target-to-background ratio (TBR) and compared with available results from right heart catheterization (RHC) or transthoracic echocardiography (TTE).

RESULTS: Thirty-three subjects demonstrated clear 18F-FDG uptake in the PA wall. In the subgroup of patients who underwent RHC (n = 10), the mean PA pressure was significantly higher in the group with PA 18F-FDG uptake compared with the group without uptake (34.4 ± 7.2 mm Hg vs 25.6 ± 9.3 mm Hg; P = 0.003), and 9 (90%) patients with PA 18F-FDG uptake had PH when a mean PA pressure cutoff of 25 mm Hg was used compared with 18 (45%) in the nonuptake group (P < 0.05). In the subgroup that underwent TTE, signs of PH were present in a significantly higher number of patients with PA 18F-FDG uptake (14 [51.9%] vs 37 [29.8%]; P < 0.05). Qualitative assessment of 18F-FDG uptake in the PA wall showed a sensitivity of 33% and specificity of 96% for separating patients with PH based on RHC-derived PA pressures. SUVmax and TBR in the PA wall correlated with PA pressure derived from RHC and/or TTE.

CONCLUSIONS: We demonstrate that 18F-FDG uptake by PET/CMR in the PA is associated with PH and that its intensity correlates with PA pressure.

来源:JACC Cardiovasc Imaging,查看原文。版权归原作者所有。

引用

  1. Maier A, Liao SL, Lescure T, et al. Pulmonary Artery 18F-Fluorodeoxyglucose Uptake by PET/CMR as a Marker of Pulmonary Hypertension in Sarcoidosis. JACC Cardiovasc Imaging. 2021. PMID: 34274283. doi:10.1016/j.jcmg.2021.05.023

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。